Late Sodium Current Block for Drug-Induced Long QT Syndrome: Results from a Prospective Clinical Trial

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 2, 2016, Pages 214-223

  Johannesen, L ^a,b   Vicente, J ^a,c,d   Mason, J W ^e,f   Erato, C ^e   Sanabria, C ^e   Waite Labott, K ^e   Hong, M ^g   Lin, J ^g   Guo, P ^g   Mutlib, A ^g   Wang, J ^g   Crumb, W J ^h   Blinova, K ^a   Chan, D ^a   Stohlman, J ^a   Florian, J ^c   Ugander, M ^a,b   Stockbridge, N ^c   Strauss, D G ^a,b  

^a CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF ZARAGOZA   (Spain)

^e University of Utah ^*  (United States)

^f UNIVERSITY OF UTAH   (United States)

^g Frontage Laboratories Inc   (United States)

^h ZENAS TECHNOLOGIES LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DILTIAZEM; DOFETILIDE; LIDOCAINE; MEXILETINE; MOXIFLOXACIN; POTASSIUM CHANNEL HERG; SODIUM; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; PHENETHYLAMINE DERIVATIVE; QUINOLONE DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT; SULFONAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG INDUCED DISEASE; DRUG INDUCED LONG QT SYNDROME; DRUG SAFETY; FEMALE; GENE OVEREXPRESSION; HEART RATE; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; MALE; PHASE 1 CLINICAL TRIAL; POTASSIUM CURRENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SODIUM CURRENT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; ELECTROCARDIOGRAPHY; YOUNG ADULT;

ADULT; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DILTIAZEM; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; FLUOROQUINOLONES; HEART RATE; HUMANS; LIDOCAINE; LONG QT SYNDROME; MALE; MEXILETINE; PHENETHYLAMINES; PROSPECTIVE STUDIES; SODIUM CHANNEL BLOCKERS; SULFONAMIDES; YOUNG ADULT;

EID: 84957109639     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.205     Document Type: Article

References (39)

1. Roden, D. M. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350, 1013-1022 (2004).
2. Stockbridge, N., Morganroth, J., Shah, R. R. & Garnett, C. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated? Drug Saf. 36, 167-182 (2013).
3. AZCert. CredibleMeds. (2014). Accessed 17 October 2014.
4. Sager, P. T., Gintant, G., Turner, J. R., Pettit, S. & Stockbridge, N. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am. Heart J. 167, 292-300 (2014).
5. Darpo, B. et al. Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin. Pharmacol. Ther. 97, 326-335 (2015).
6. Lu, Z. et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci. Transl. Med. 4, 131ra50 (2012).
7. Trudeau, M. C., Warmke, J. W., Ganetzky, B. & Robertson, G. A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269, 92-95 (1995).
8. Redfern, W. S. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45 (2003).
9. Antzelevitch, C. et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904-910 (2004).
10. Wu, L. et al. Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc. Res. 77, 481-488 (2008).
11. Sanguinetti, M. C. & Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature 440, 463-469 (2006).
12. Martin, R. L., McDermott, J. S., Salmen, H. J., Palmatier, J., Cox, B. F. & Gintant, G. A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J. Cardiovasc. Pharmacol. 43, 369-379 (2004).
13. Chézalviel-Guilbert, F., Davy, J. M., Poirier, J. M. & Weissenburger, J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. J. Am. Coll. Cardiol. 26, 787-792 (1995).
14. Belardinelli, L. et al. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J. Pharmacol. Exp. Ther. 344, 23-32 (2013).
15. Shimizu, W. & Antzelevitch, C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 96, 2038-2047 (1997).
16. O'Hara, T. & Rudy, Y. Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species. Am. J. Physiol. Heart Circ. Physiol. 302, H1023-H1030 (2012).
17. Johannesen, L. et al. Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin. Pharmacol. Ther. 96, 549-558 (2014).
18. Johannesen, L. et al. Improving the assessment of heart toxicity for all new drugs through translational regulatory science. Clin. Pharmacol. Ther. 95, 501-508 (2014).
19. Nakaya, H., Schwartz, A. & Millard, R. W. Reflex chronotropic and inotropic effects of calcium channel-blocking agents in conscious dogs. Diltiazem, verapamil, and nifedipine compared. Circ. Res. 52, 302-311 (1983).
20. Bennett, P., McKinney, L., Begenisich, T. & Kass, R. S. Adrenergic modulation of the delayed rectifier potassium channel in calf cardiac Purkinje fibers. Biophys. J. 49, 839-848 (1986).
21. Stass, H. & Kubitza, D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J. Antimicrob. Chemother. 43 (suppl. B), 83-90 (1999).
22. Wang, D. W., Yazawa, K., Makita, N., George, A. L. Jr. & Bennett, P. B. Pharmacological targeting of long QT mutant sodium channels. J. Clin. Invest. 99, 1714-1720 (1997).
23. Rosero, S. Z., Zareba, W., Robinson, J. L. & Moss, A. J. Gene-specific therapy for long QT syndrome: QT shortening with lidocaine and tocainide in patients with mutation of the sodium-channel gene. Ann. Noninvasive Electrocardiol. 2, 274-278 (1997).
24. Schwartz, P. J. et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na1 channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 92, 3381-3386 (1995).
25. Gao, Y. et al. Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in Timothy syndrome. Circ. Arrhythm. Electrophysiol. 6, 614-622 (2013).
26. Persson, F., Andersson, B., Duker, G., Jacobsen, I. & Carlsson, L. Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre. Eur. J. Pharmacol. 558, 133-143 (2007).
27. Giardina, E. G. & Wechsler, M. E. Low dose quinidine-mexiletine combination therapy versus quinidine monotherapy for treatment of ventricular arrhythmias. J. Am. Coll. Cardiol. 15, 1138-1145 (1990).
28. Yang, T. et al. Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation 130, 224-234 (2014).
29. Duff, H. J., Mitchell, L. B., Manyari, D. & Wyse, D. G. Mexiletinequinidine combination: electrophysiologic correlates of a favorable antiarrhythmic interaction in humans. J. Am. Coll. Cardiol. 10, 1149-1156 (1987).
30. Duff, H. J., Roden, D., Primm, R. K., Oates, J. A. & Woosley, R. L. Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. Circulation 67, 1124-1128 (1983).
31. Yin, H. et al. Actions of lidocaine on reentrant ventricular rhythms in the subacute myocardial infarction period in dogs. Am. J. Physiol. 272 (1 Pt 2), H299-H309 (1997).
32. Aupetit, J. F. et al. Profibrillatory effects of lidocaine in the acutely ischemic porcine heart. J. Cardiovasc. Pharmacol. 25, 810-816 (1995).
33. Carson, D. L. et al. Relationship between an arrhythmogenic action of lidocaine and its effects on excitation patterns in acutely ischemic porcine myocardium. J. Cardiovasc. Pharmacol. 8, 126-136 (1986).
34. Vicente, J. et al. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil. J. Am. Heart Assoc. 4, e001615 (2015).
35. US Food and Drug Administration. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. (2005). Accessed 17 October 2014.
36. Fridericia, L. S. Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med. Scand. 53, 469-486 (1920).
37. Badilini, F., Vaglio, M. & Sarapa, N. Automatic extraction of ECG strips from continuous 12-lead holter recordings for QT analysis at prescheduled versus optimized time points. Ann. Noninvasive Electrocardiol. 14 (suppl. 1), S22-S29 (2009).
38. Smetana, P., Batchvarov, V., Hnatkova, K., John Camm, A. & Malik, M. Sex differences in the rate dependence of the T wave descending limb. Cardiovasc. Res. 58, 549-554 (2003).
39. Crumb, W. J. Jr, Pigott, J. D. & Clarkson, C. W. Description of a nonselective cation current in human atrium. Circ. Res. 77, 950-956 (1995).